Business Wire

CA-BEHAVIOSEC

21.4.2021 09:02:13 CEST | Business Wire | Press release

Share
Biometrics Experts and New Study Highlight How Behavioral Biometrics Supports Strict Regulation and Offers Better Data Privacy Protections

BehavioSec , the industry pioneer and technology leader for behavioral biometrics and continuous authentication, today announced new findings that organizations and consumers can feel more comfortable with wider use of behavioral biometrics to safeguard their online digital experiences and identities.

Following a year of digital transformation on a societal level, the demand for better online user experience and a stronger level of digital identity protection has become essential. With a year when the world has seen a combination of personal data theft with new rulings and proposed legislation, like the EU Schrems II in July 2020 and the US National Biometrics Information Privacy Act in August [US Senators Merkley, D-OR and Sanders, I-VT], the need for expert guidance has never been higher. BehavioSec shares this research and a company milestone to highlight how behavioral biometrics can be adopted transparently with clear benefits, and in compliant fashion with comprehensive data protection laws. These include measures like the European General Data Protection Regulation (GDPR), the European Commission’s PSD2/SCA and its Open Banking mandate, the US California Consumer Privacy Act (CCPA) and similar, anticipated requirements of regulations proposed in other regions.

To validate the safe use of behavioral biometrics at a time when headlines are full of allegations about technologies like facial recognition and “deep fake” simulations being abused, BehavioSec sponsored the report, “2021 Global Data Privacy Regulation of Physical & Behavioral Biometrics” by respected industry research firm Goode Intelligence . In the report, Chief Analyst Alan Goode dives into the relevance of current and proposed global privacy and data protection legislation on the successful and compliant adoption of biometrics technology for authentication and identity verification, and addresses the key questions organizations and consumers are asking:

  • Where do the next wave of behavioral-based technologies fit?
  • How do they impact our delicate balance between security, privacy, and regulation?
  • Are they covered under existing and proposed regulation?
  • Will behavior-based technology make matters worse - or much better?

Leveraging global bank customer input, extensive research, and legal opinion from attorneys at international law firm Osborne Clarke , the paper outlines how enterprises can confidently use behavioral biometrics while complying with some of the strictest privacy and data protection laws in the world, including GDPR, industry payment regulations like PSD2 SCA, and 3D Secure 2.0 technology.

“As we move more of our personal and business tasks online, it is becoming increasingly important to secure digital channels,” says Goode. “Mobile security is more important than ever before and behavioral biometric technology has proven itself as a vital tool in enabling secure access to digital services, preventing fraudsters from gaining access, all while remaining compliant to GDPR, among others.”

A US-based webcast, “Biometrics & Digital Identity Verification – 2021 Data Protection & Privacy Regulation Insights” will be broadcast on May 25, 2021 featuring a presentation by Alan Goode on his report’s findings and offer further insight on data privacy, digital transformation and fighting fraud and cybercrime using biometrics. Viewers can register to watch the webinar hosted by BehavioSec and IDG including a discussion between CSO’s Bob Bragdon, Alan Goode and an expert panel including Dr. Shane Shook, Financial Crimes Investigator and Venture Consultant at ForgePoint Capital, Jordan Blake, BehavioSec Vice President of Products, and Jake Bernstein J.D., attorney at Focal PLLC and former Washington State Assistant Attorney General.

“It is crucial to proactively stir these debates now on how new technologies define identity and authentication, before assumptions and lack of transparency – even if unintended – irrevocably shake public and policymakers’ trust,” added Jake Bernstein, who specialized in prosecuting consumer protection cases during his time in the U.S. Washington State Attorney General’s office. “The boundary between improving digital trust and triggering privacy and identity crises does not have to be a slippery slope where biometric-based systems are concerned. Yet, perceived missteps and alleged abuse of facial-recognition and other innovations to-date show us what stakeholders, including businesses, have to avoid.”

Additionally, on May 26th at 3:00pm BST/4:00pm CEST, Goode will host a second webcast, “2021 Global Regulation of Physical & Behavioral Biometrics for Digital Identity Verification” , to present his research on the impacts of privacy and data protection regulation on the implementation of biometrics by businesses, particularly across the European Union. As the Founder, CEO, and Chief Analyst of Goode Intelligence, Goode is a respected expert in information security and biometrics and will offer insights on how businesses may be able to consider their specific use cases and possible exceptions for explicit consent according to GDPR regulation. Goode will be joined by BehavioSec and international law firm Osborne Clarke, who BehavioSec commissioned to advise on the regulatory impact to customer deployments of the BehavioSec behavioral biometrics platform , specifically within the German banking sector.

“There’s no question that technology vendors need to continue to work collaboratively with government and business to ensure better protection and experience for consumers and employees while staying fully compliant,” said BehavioSec CEO Neil Costigan. “As the pioneer in this space, we’re offering this research to the market to open the dialogue, and we’re also demonstrating and modeling compliance as a company. Beyond our ongoing support of GDPR and security best practices, we are happy to share our recent SOC2 Type1 certification and our active program for Type 2 and ISO 27001.”

To access this research, the public can download Alan Goode’s report and join the public webcasts with CSO [IDG] in the US on May 25th and with Goode Intelligence in Europe on May 26th .

About BehavioSec

BehavioSec is the industry pioneer and technology leader for behavioral biometrics and continuous authentication, safeguarding millions of users and billions of transactions today.

Deployed across Global 2000 companies to dramatically reduce fraud, friction, threat, and theft, BehavioSec verifies and protects human digital identities by understanding how we uniquely type and swipe across our ever-changing devices. Whether used in the Cloud or on-premises, BehavioSec delivers the superior user experience, precision, and scale needed by organizations to keep customers engaged while catching evasive, real-time attacks other solutions miss.

Founded in the Nordics in 2008 out of groundbreaking research, industry-recognized BehavioSec partners with market leaders and organizations like DARPA, and has earned investment from top investment firms like ForgePoint Capital, Cisco, ABN AMRO, Conor Ventures, and Octopus Ventures. Headquartered in San Francisco, CA with offices worldwide, BehavioSec is ready to help you reduce risk, improve compliance, and digitally transform your distributed workforce and customer experience. www.behaviosec.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release

In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release

IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye